JP2008538919A - ＦｃＲｎ抗体およびその使用 - Google Patents

ＦｃＲｎ抗体およびその使用 Download PDF

Info

Publication number
JP2008538919A
JP2008538919A JP2008508906A JP2008508906A JP2008538919A JP 2008538919 A JP2008538919 A JP 2008538919A JP 2008508906 A JP2008508906 A JP 2008508906A JP 2008508906 A JP2008508906 A JP 2008508906A JP 2008538919 A JP2008538919 A JP 2008538919A
Authority
JP
Japan
Prior art keywords
human
antibody
fcrn
binding
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008508906A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008538919A5 (OSRAM
Inventor
デリー チャールズ ルーペニアン，
シュリーラム アキレシュ，
グレゴリー ジェームス クリスティアンソン，
ステフカ ペトコバ，
トーマス ジェイ スプロール，
エマニュエル ペサベント，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jackson Laboratory
Original Assignee
Jackson Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jackson Laboratory filed Critical Jackson Laboratory
Publication of JP2008538919A publication Critical patent/JP2008538919A/ja
Publication of JP2008538919A5 publication Critical patent/JP2008538919A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2008508906A 2005-04-29 2006-04-14 ＦｃＲｎ抗体およびその使用 Pending JP2008538919A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67641205P 2005-04-29 2005-04-29
PCT/US2006/014182 WO2006118772A2 (en) 2005-04-29 2006-04-14 Fcrn antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2008538919A true JP2008538919A (ja) 2008-11-13
JP2008538919A5 JP2008538919A5 (OSRAM) 2009-07-09

Family

ID=37105335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008508906A Pending JP2008538919A (ja) 2005-04-29 2006-04-14 ＦｃＲｎ抗体およびその使用

Country Status (5)

Country Link
US (1) US20100266530A1 (OSRAM)
EP (1) EP1879920A2 (OSRAM)
JP (1) JP2008538919A (OSRAM)
CA (1) CA2606378A1 (OSRAM)
WO (1) WO2006118772A2 (OSRAM)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016511280A (ja) * 2013-03-15 2016-04-14 アフィボディ・アーベー 新しいポリペプチド
JP2017513902A (ja) * 2014-04-25 2017-06-01 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． アルファ−フェトプロテイン（ａｆｐ）を操作するための方法
JP2017520754A (ja) * 2014-04-25 2017-07-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 免疫媒介性疾患を有する対象を処置するための組成物および方法
JP2018522578A (ja) * 2015-05-12 2018-08-16 シンティミューン，インコーポレイティド ヒト化型親和性成熟抗ＦｃＲｎ抗体
JP2020022487A (ja) * 2013-03-15 2020-02-13 アフィボディ・アーベー 新しいポリペプチド
JP2024529081A (ja) * 2021-08-13 2024-08-01 舒泰神（北京）生物製薬股フン有限公司 Ｆｃｒｎを特異的に認識する抗体およびその使用

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009524664A (ja) * 2006-01-25 2009-07-02 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 自己／アロ免疫疾患の治療のための抗−ｆｃｒｎ抗体
US20100166734A1 (en) * 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
EP2195028A2 (en) 2007-09-18 2010-06-16 The Jackson Laboratory Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
TWI593423B (zh) * 2008-04-25 2017-08-01 戴埃克斯有限公司 Ｆｃ受體結合蛋白
AU2015200004B2 (en) * 2008-04-25 2017-02-16 Bioverativ Therapeutics Inc. Antibodies against fcrn and use thereof
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
US8232067B2 (en) 2009-05-29 2012-07-31 Brigham & Women's Hospital, Inc. Disrupting FCRN-albumin interactions
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
PH12013502378A1 (en) * 2011-06-02 2014-01-06 Dyax Corp Fc RECEPTOR BINDING PROTEINS
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
WO2014072481A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
JP6620094B2 (ja) * 2013-11-26 2019-12-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 免疫応答を調節するための組成物および方法
CA2934644C (en) 2013-12-24 2023-11-21 Argen-X N.V. Fcrn antagonists and methods of use
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
NZ726089A (en) * 2014-04-30 2017-12-22 Hanall Biopharma Co Ltd Antibody binding to fcrn for treating autoimmune diseases
US10323066B2 (en) 2014-09-17 2019-06-18 Affibody Ab Neonatal Fc receptor binding dimer and methods of use
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
CN106957365B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
MX2020005981A (es) 2017-12-08 2020-08-24 Argenx Bvba Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.
EP3802590A2 (en) 2018-06-08 2021-04-14 Argenx BVBA Compositions and methods for treating immune thrombocytopenia
MA53903A (fr) 2018-10-16 2021-08-25 UCB Biopharma SRL Méthode de traitement de la myasthénie grave
EP3980063A1 (en) 2019-06-07 2022-04-13 Argenx BVBA Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration
KR20220148804A (ko) 2020-01-08 2022-11-07 아르젠엑스 비브이 천포창 장애의 치료 방법
JP2023531451A (ja) * 2020-06-17 2023-07-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 遺伝子療法患者の治療のための組成物及び方法
CN119013290A (zh) * 2022-04-13 2024-11-22 Ose免疫疗法公司 用于选择性清除抗体的新型分子
JP2025522251A (ja) 2022-05-30 2025-07-15 ハナル バイオファーマ カンパニーリミテッド 安定性が向上した抗ＦｃＲｎ抗体またはこの抗原結合断片
CA3258004A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/HSA BONDING MOLECULES AND METHODS OF USE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013912A2 (en) * 2003-08-08 2005-02-17 The Research Foundation Of State University Of Newyork Anti-fcrn antibodies for treatment of auto/allo immune conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6992234B2 (en) * 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013912A2 (en) * 2003-08-08 2005-02-17 The Research Foundation Of State University Of Newyork Anti-fcrn antibodies for treatment of auto/allo immune conditions

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016511280A (ja) * 2013-03-15 2016-04-14 アフィボディ・アーベー 新しいポリペプチド
JP2020022487A (ja) * 2013-03-15 2020-02-13 アフィボディ・アーベー 新しいポリペプチド
JP2017513902A (ja) * 2014-04-25 2017-06-01 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． アルファ−フェトプロテイン（ａｆｐ）を操作するための方法
JP2017520754A (ja) * 2014-04-25 2017-07-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 免疫媒介性疾患を有する対象を処置するための組成物および方法
JP2018522578A (ja) * 2015-05-12 2018-08-16 シンティミューン，インコーポレイティド ヒト化型親和性成熟抗ＦｃＲｎ抗体
JP2022008301A (ja) * 2015-05-12 2022-01-13 シンティミューン，インコーポレイティド ヒト化型親和性成熟抗ＦｃＲｎ抗体
JP2024529081A (ja) * 2021-08-13 2024-08-01 舒泰神（北京）生物製薬股フン有限公司 Ｆｃｒｎを特異的に認識する抗体およびその使用
JP7755725B2 (ja) 2021-08-13 2025-10-16 ジャンスー バイオジェッテイ バイオテクノロジー カンパニー リミテッド Ｆｃｒｎを特異的に認識する抗体およびその使用

Also Published As

Publication number Publication date
US20100266530A1 (en) 2010-10-21
EP1879920A2 (en) 2008-01-23
CA2606378A1 (en) 2006-11-09
WO2006118772A2 (en) 2006-11-09
WO2006118772A9 (en) 2008-03-06
WO2006118772A3 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
US20100266530A1 (en) FcRN ANTIBODIES AND USES THEREOF
JP7819160B2 (ja) マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
JP7312168B2 (ja) Ｃｄ１３７に結合するシングルドメイン抗体
CA3092456C (en) Anti-tigit antibody and use thereof
JP2023002706A (ja) 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法
JP6632984B2 (ja) 抗ＥＧＦＲｖＩＩＩ抗体およびその使用
EP3981790A1 (en) Binding molecule specific for cd73 and use of binding molecule
JP2018520991A (ja) 抗ｃｄ７１抗体、活性化可能抗ｃｄ７１抗体、およびその使用方法
JP2018520092A (ja) 抗ＩＴＧａ３抗体、活性化可能抗ＩＴＧａ３抗体、およびその使用方法
JP2018529317A (ja) メソテリン及びｃｄ３に結合する二重特異性抗体構築物
CN106163556A (zh) 基质金属蛋白酶底物和其它可切割部分及其使用方法
JP7539834B2 (ja) ガレクチン－３に対する抗体及びその使用方法
EP3074421A1 (en) Antibodies against ccr9 and applications thereof
US20220227850A1 (en) Binding molecules
US12509513B2 (en) Anti-L1CAM antibodies and uses thereof
JP2024507628A (ja) 免疫グロブリン軽鎖抗体およびその使用
JP6790307B2 (ja) 抗ヒトｔｌｒ７抗体
CN103588882B (zh) 针对人cd22抗体的抗独特型抗体及其应用
US11629184B2 (en) Calcitonin gene-related peptide (CGRP) antagonist antibodies
US12630619B2 (en) Immunoglobulin light chain antibodies and uses thereof
RU2786434C2 (ru) Антитело к tigit и его использование
TW202509069A (zh) 抗cd161抗體及其使用方法
CN121219323A (zh) 抗cldn6抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111018

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120308